Drug intelligence / Profile preview

pf-07265807

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07265807 is a selective small-molecule inhibitor of the receptor tyrosine kinases MERTK (Mer proto-oncogene, tyrosine kinase) and AXL. These kinases are part of the tumor-associated macrophage kinase (TAMK) family and play roles in immune homeostasis and cancer progression. Inhibition of MERTK and AXL by PF-07265807 is designed to lower the threshold for immune activation, thereby promoting antitumor immunity. Preclinical studies demonstrated that PF-07265807 has antitumor activity both as monotherapy and in combination with anti-programmed cell death protein 1 (anti-PD-1) antibodies. The drug was developed by Pfizer for use in advanced or metastatic solid tumors but its clinical development was discontinued after phase 1 trials[2][4][5][6][8].

Targets

AXL (AXL receptor tyrosine kinase)MERTK (MER proto-oncogene, tyrosine kinase)

Beyond the preview

Go deeper on pf-07265807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pf-07265807.